Previous 10 | Next 10 |
Oramed Pharmaceuticals (NASDAQ: ORMP ) initiated with Buy rating and $7 (136% upside) at Ladenburg Thalmann. Shares up 3% premarket. More news on: Oramed Pharmaceuticals Inc., PhaseBio Pharmaceuticals, Inc., Bicycle Therapeutics plc, Healthcare stocks news, Stocks on the move, ...
Microbot Medical (NASDAQ: MBOT ) -10% on self-cleaning shunt data . More news on: Microbot Medical Inc., Neurotrope, Inc., The Wendy's Company, Stocks on the move, Read more ...
Neurotrope, Inc. (NASDAQ:NTRP) is not starting the week off on the right foot. After announcing that its Alzheimer’s drug failed in its latest trial, NTRP stock tumbled around 80% Monday. Here’s what we know. NTRP Stock Plunges 80% On Monday, September 9, drug developer ...
Gainers : ACADIA Pharmaceuticals (NASDAQ: ACAD ) +60% . Changyou.com Limited (NASDAQ: CYOU ) +49% . Key Energy Services (NYSE: KEG ) +29% . Cesca Therapeutics (NASDAQ: KOOL ) +25% . Hovnanian Enterprises (NYSE: HOV ) +24% . Gulfport Energy Corporation (NASDAQ: GPOR ) +20% . Independe...
Thinly traded nano cap Neurotrope ( NTRP -79.2% ) slumps on a 14x surge in volume in reaction to unsuccessful results from a confirmatory Phase 2 clinical trial evaluating Bryostatin-1 in patients with moderate-to-severe Alzheimer's disease. More news on: Neurotrope, Inc., Healthcare...
Neurotrope (NASDAQ: NTRP ) -76% on announcing top-line results from Phase 2 study of Bryostatin-1. More news on: Neurotrope, Inc., PaySign, Inc., Cassava Sciences, Inc., Stocks on the move, Read more ...
NEW YORK , Sept. 9, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in modera...
Vancouver, Canada (ABN Newswire) - Join Ellis Martin for an exclusive conversation pertinent to the world of the disruptive disease called Alzheimers. Can this dreadful malady be reversed offering hope to victims and their families? Can neurons in the brain be regrown? Is there a cure for A...
NEW YORK , Aug. 13, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that an article highlighting the synaptic deficiency hypot...
NEW YORK , Aug. 5, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided an update on clinical and corporate developments, includin...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Dynamic Content-to-Commerce FAST Channel Reinvents Monetization Models SUNRISE, FL / ACCESSWIRE / July 18, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, today announced that it has partnered with OTT ("over-the-top") services...
Allows Consumers to Pay for Accommodations Through Interest-free Installments with Convenient and Flexible Payment Options when Booking Travel Seamless Integration Enables Marketing Opportunities in Social Media Travel Package Campaigns and Direct-to-Consumer Marketing Channels to Drive Sale...